BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 8822949)

  • 21. The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.
    Chieregato K; Zanon C; Castegnaro S; Bernardi M; Amati E; Sella S; Rodeghiero F; Astori G
    Blood Transfus; 2017 Jan; 15(1):93-100. PubMed ID: 27136441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shaping of CD56
    Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2019; 10():547. PubMed ID: 30949182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Cytomegalovirus Reactivation and Expansion of CD56
    Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).
    Chiorean EG; Dylla SJ; Olsen K; Lenvik T; Soignier Y; Miller JS
    Blood; 2003 May; 101(9):3527-33. PubMed ID: 12511422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.
    Domaica CI; Fuertes MB; Uriarte I; Girart MV; Sardañons J; Comas DI; Di Giovanni D; Gaillard MI; Bezrodnik L; Zwirner NW
    PLoS One; 2012; 7(12):e51677. PubMed ID: 23240056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
    Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
    Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
    Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
    Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer cell lytic activity and CD56(dim) and CD56(bright) cell distributions during and after intensive training.
    Suzui M; Kawai T; Kimura H; Takeda K; Yagita H; Okumura K; Shek PN; Shephard RJ
    J Appl Physiol (1985); 2004 Jun; 96(6):2167-73. PubMed ID: 14752119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
    Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
    Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
    Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
    Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
    Voss SD; Daley J; Ritz J; Robertson MJ
    J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD56
    Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
    Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
    Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
    J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biology of human natural killer-cell subsets.
    Cooper MA; Fehniger TA; Caligiuri MA
    Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.